Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Julio Raul Fernandez Masso

Osvaldo Reyes Acosta

Mario Pablo Estrada Garcia

Alexis Musacchio Lasa

Diana Garcia Del Barco Herrera

Rebeca Martinez Rodriguez

Isis Del Carmen Torrens Madrazo

Ariana Garcia Ojalvo

Jose De La Fuente Garcia

Alina Seralena Menendez

Elder Pupo Escalona

Martha De Jesus Gonzalez Griego

Gerardo Enrique Guillen Nieto

Glay Chinea Santiago

Jorge Amador Berlanga Acosta

Maribel Guerra Vallespi

Jorge Berlanga Acosta

Ania De La Nuez Veulens

Rolando Eduardo Rodriguez Fernandez

Maribel Guerra Valespi

Jose Suarez Alba

Isabel Guillen Perez

Brizaida Maylin Oliva Arguelles

Jeovanis Gil Valdes

This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.

Cancer therapy method

Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.

Peptidic growth hormone secretagogues analog compounds and preparations thereof

This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.

Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect

Streptokinase mutants

The present invention is related to the field of biotechnology and genetic engineering techniques, particularly to a method for obtaining mutants obtain from streptokinase, to the molecules obtained from this method, as well as the expression vectors and microorganisms for recombinant obtaining. The object of the present invention is to achieve streptokinase mutants from modifications of skc-2 gene coding for streptokinase SKC-2 (Heberkinase&reg;), such that the obtained mutants conserve their capacity for plasminogen activator complex formation having reduced antigenicity, that could constitute preferred alternatives to native streptokinase for thrombolytic therapy. The molecules obtained from present invention can be used in the treatment of disorders as myocardial infarct, pulmonary thromboembolism, surgical complications and other cases of thrombosis.

Growing community of inventors

La Habana, Cuba

Julio Raul Fernandez Masso